Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

30,155 total articles

Morgan Stanley Reassesses Q1 Results for Payments Group, Keeps Cautious Views on Execution and Profitability

Morgan Stanley Reassesses Q1 Results for Payments Group, Keeps Cautious Views on Execution and Profitability

Morgan Stanley reviewed first-quarter 2026 results from three payments and processing companies and left its overall stance cautious across the group. The firm adjusted price targets and reiterated ratings while calling out execution timing at Jack Henry, take-rate compression at Marqeta and sustained high marketing spend at NerdWallet as the prima…

Trump Reportedly Poised to Remove FDA Commissioner Marty Makary

Trump Reportedly Poised to Remove FDA Commissioner Marty Makary

President Donald Trump is reportedly planning to remove U.S. Food and Drug Administration Commissioner Marty Makary, though the course of action is not finalized and could change. Makary, a surgical oncologist at Johns Hopkins and a published author on healthcare costs and systemic issues in modern medicine, was confirmed as FDA commissioner in Mar…

Stifel: US Non-Residential Construction Spending Inches Up 0.1% in March

Stifel: US Non-Residential Construction Spending Inches Up 0.1% in March

The U.S. Census Bureau data reviewed by Stifel shows total non-residential construction spending rose 0.1% year-over-year in March after a 0.2% year-over-year decline the prior month. Gains were concentrated in non-building segments such as sewage and waste disposal, conservation and development, and power, while overall building spending fell, des…

Moderna Shares Jump After Company Confirms Hantavirus Vaccine Research

Moderna Shares Jump After Company Confirms Hantavirus Vaccine Research

Moderna Inc. confirmed it is conducting early-stage research on vaccines targeting hantaviruses, collaborating with the U.S. Army Medical Research Institute of Infectious Diseases and the Vaccine Innovation Center at Korea University College of Medicine. The announcement coincided with a 16% surge in the company’s shares and follows a recent outbre…

Spanish Stocks Slip as IBEX 35 Closes Nearly 1% Lower

Spanish Stocks Slip as IBEX 35 Closes Nearly 1% Lower

The IBEX 35 ended the trading session in Madrid down 0.95%, weighed by losses in the Consumer Goods, Consumer Services and Financial Services & Real Estate sectors. Among large-cap movers, Amadeus IT, Corporacion Acciona Energias Renovables and Repsol were the top gainers, while International Consolidated Airlines Group, Banco de Sabadell and Grifo…

Paris equities close lower as CAC 40 slips 1.09% amid sector losses

Paris equities close lower as CAC 40 slips 1.09% amid sector losses

France's main equity gauges ended Friday in negative territory, with the CAC 40 sliding 1.09% and the broader SBF 120 down 1.01%. Industrial, healthcare and consumer goods names were among the largest drags, while select technology and services stocks posted gains. Market volatility as measured by the CAC 40 VIX held at a 52-week high, and commodit…

Belgian equities dip as BEL 20 slips 0.12% at Friday close

Belgian equities dip as BEL 20 slips 0.12% at Friday close

Belgian stocks finished lower on Friday with the BEL 20 index retreating 0.12% at the close in Brussels. Sector-level declines in Consumer Goods, Financials and Industrials drove the market lower even as individual gains lifted several components, including Umicore and Melexis to 52-week highs. Broader market breadth favored decliners over advancer…

Forward Air Plunges After Strategic Review Produces No Bids, Earnings Miss and Customer Risk Revealed

Forward Air Plunges After Strategic Review Produces No Bids, Earnings Miss and Customer Risk Revealed

Forward Air shares tumbled more than 38% after the company said its strategic-alternatives review produced no offers despite extensive negotiations. The move came after disappointing Q1 2026 results, a sizable potential customer transition representing roughly $250 million of annual revenue, margin weakness in intermodal operations, and rapid analy…